New AntiVirals 

for Infections 

with Pandemic 

Potential

For infectious disease management and control, vaccines are considered golden countermeasures 
but are not the most adequate tool for mitigating 
the early effects of an outbreak.

Taking the recent COVID-19 pandemic as an example, access to broadly applicable therapeutic antivirals would have had a major impact, decreasing the human toll of the disease, and alleviating the burden carried by health care systems. It is urgent to focus resources and efforts on the development of broad spectrum antiviral drugs against unknown pathogens.

The New AntiVirals for Infections with Pandemic Potential (NAVIPP) consortium aims to strengthen the EU’s readiness and response capacity to viral threats by assembling an international R&D platform for antiviral drug development against pandemic prone pathogens.

navipp by
numbers

0

partners

0

countries

0

years EU-funded
project

0

millions €

NEWS

  • Download our A0 Poster

    For partners: Want to showcase NAVIPP activities? Download our A0 poster! If you’re looking for a clear, visual way to communicate about the NAVIPP project, our A0 poster is the perfect tool. Whether you’re attending a conference, meeting with partners, or simply want to raise awareness, this poster gives a concise and impactful overview of…

  • NAVIPP at the European Congress of Virology 2025

    NAVIPP was proud to be represented at the European Congress of Virology 2025, held in the beautiful setting of Cavtat and Dubrovnik, Croatia. Audrey Richard (ERINHA) introduced the project to an audience of leading virology experts, highlighting NAVIPP’s ambition to develop broad-spectrum antivirals as a key pillar of European pandemic preparedness. Through its dual-track approach — combining strategic innovation and practical readiness — NAVIPP is…

  • NAVIPP project poised to contribute to WHO’s new R&D Blueprint for Epidemics

    WHO’s New Pathogens Prioritization Framework In 2015, the World Health Organization (WHO), at the request of almost 200 member states, developed its first Research & Development (R&D) Blueprint for Action to Prevent Epidemics focusing on a number of specific severe infectious diseases for which no medical countermeasures (MCMs) were available. Launched for the first time…